Background Specific reversal agents for non–vitamin K antagonist oral anticoagulants are
lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant …

Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU
and several other countries for the prevention of venous thromboembolism after elective hip …

Aims The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim
Pharma GmbH & Co. KG), shows potential as an oral antithrombotic agent. Two double‐blind, …

Background Idarucizumab, a monoclonal antibody fragment, was developed to reverse the
anticoagulant effect of dabigatran. Methods We performed a multicenter, prospective, open-…

Background and Objective: Dabigatran etexilate is an oral direct thrombin inhibitor in clinical
development for the prevention and treatment of thromboembolic disorders. Following oral …

The pharmacokinetics and metabolism of the direct thrombin inhibitor dabigatran (BIBR 953
ZW, β-alanine, N-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-…

The direct thrombin inhibitor dabigatran etexilate is currently in phase III of development for
the prophylaxis and treatment of thromboembolic disorders, with three trials completed in …

This is the first evaluation of dabigatran, an oral direct thrombin inhibitor, in patients with atrial
fibrillation (AF). Patients (n = 502) were randomized to receive blinded doses of 50-, 150-, …

Dabigatran etexilate is an oral low‐molecular‐weight direct thrombin inhibitor. Following oral
administration, dabigatran etexilate is rapidly converted to its active form, dabigatran. The …

Objectives To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran
in healthy elderly subjects; to assess the intra- and interindividual variability of dabigatran …